Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

U. Lindblad, Gunnar Lindberg, Nils-Ove Månsson, Jonas Ranstam, Maria Tyrberg, S. Jansson, K. Lindwall, Mona Svärdh, L. Kindmalm, Arne Melander

Research output: Contribution to journalArticlepeer-review

11 Citations (SciVal)

Abstract

The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.
Original languageEnglish
Pages (from-to)185-188
JournalDiabetes, Obesity and Metabolism
Volume13
Issue number2
DOIs
Publication statusPublished - 2011

Subject classification (UKÄ)

  • Endocrinology and Diabetes

Keywords

  • IFG
  • prevention
  • primary care
  • randomized trial
  • sulphonylurea
  • type 2
  • diabetes

Fingerprint

Dive into the research topics of 'Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)'. Together they form a unique fingerprint.

Cite this